Soluble ST2 (sST2) Levels in the Management of Carcinoid Heart Disease in Patients with Neuroendocrine Cancer
Introduction: The identification of a sensitive biomarker to detect the presence and severity of carcinoid heart disease could allow more selective use of clinical and echocardiographic screening. ST2 is a protein belonging to the family of interleukin 1 receptors, present both in the isoform of transmembrane (ST2L) and in the soluble one (sST2). sST2 blocks the anti-inflammatory, anti-hypertrophic, and anti-fibrotic effects of cytokine IL-33 on the myocardium and recent studies have shown that sST2 levels increase in the blood of patients diagnosed with heart failure.
Aim(s): The objective of this study was to evaluate the levels of sST2 in patients with NETs as a marker of carcinoid heart disease.
Materials and methods: We included 19 patients with advanced NETs. Patients underwent echocardiography and sST2 measurements at the time of their first evaluation. Carcinoid heart disease was defined by the presence of valvular steno- insufficiency, and signs of cardiac fibrosis. sST2 was measured with ELISA method. The cut-off adopted was 35 ng/mL.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.